Strategic Use of Bispecific Antibodies in R/R MM
Panelists discuss at what line of therapy bispecific antibodies are considered in treatment decision-making, whether they are used earlier or later in the sequence, and the factors influencing that choice, including weighing bispecifics against other options like chimeric antigen receptor (chimeric antigen receptor) T or standard therapies. They also address the clinical and molecular factors that guide the selection between B-cell maturation antigen (BCMA)– and GPRC5D-targeting bispecifics and comment on the study exploring talquetamab as a bridging strategy before BCMA CAR T therapy, highlighting the potential impact of bispecifics in this treatment paradigm.
EP: 1.Highlights from ASH 2024: Optimizing Frontline Therapy in Transplant-Eligible MM
EP: 2.Tailoring Induction Therapy in Newly Diagnosed Transplant-Eligible MM: Key Considerations
EP: 3.AURIGA Trial Highlights: Daratumumab + Lenalidomide Maintenance in Newly Diagnosed MM
EP: 4.Transplant-Ineligible NDMM: Updates from CEPHEUS and IMROZ at ASH 2024
EP: 5.Bispecifics in R/R MM: Key Data and Clinical Implications From ASH 2024 and Ongoing Trials
EP: 6.Strategic Use of Bispecific Antibodies in R/R MM
EP: 7.Sequencing Bispecifics and BCMA-Targeted Therapies in R/R MM
EP: 8.Integrating Bispecific Antibodies Into Clinical Practice
EP: 9.Looking Ahead: Major Clinical Advancements in Myeloma From ASH 2024 and What’s to Come in 2025
EP: 10.Developments in CAR T-Cell and Bispecific Therapies in R/R Multiple Myeloma
Video content above is prompted by the following:
- At what line of therapy do you consider bispecific antibodies in your treatment decision-making? Are you using them earlier or later in the treatment sequence, and what factors influence that decision?
- How do you weigh bispecific antibodies against other treatment options like CAR T or other standard therapies?
- What clinical and molecular factors do you prioritize when choosing between BCMA- and GPRC5D-targeting bispecifics?
- Please comment on this study looking at talquetamab as a bridging strategy before BCMA CAR T-cell therapy, and the potential impact of bispecifics in this treatment paradigm
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
